Brief: Erytech 9-Month Net Loss Widens To EUR 53.6 Mln

Phaxiam Therapeutics SA

06/11/2020 08:41

Nov 6 (Reuters) - Erytech Pharma SA  ERYP.PA :
    * ANNOUNCED ON THURSDAY BUSINESS UPDATE AND REPORTS
FINANCIAL
RESULTS FOR THE THIRD QUARTER OF 2020
    * CASH AND CASH EQUIVALENTS OF EUR 40.5 MILLION ($47.5
MILLION) AT
END OF SEPTEMBER 2020
    * €10 MILLION ($11.7 MILLION) IN NON-DILUTIVE FINANCING
SECURED IN
THE FORM OF STATE-GUARANTEED LOANS
    * NET LOSS FOR THE FIRST NINE MONTHS OF 2020 WAS EUR 53.6
MILLION,
UP EUR 10.3 MILLION (+24%) YEAR-OVER-YEAR, WITH A EUR 4.7
MILLION  INCREASE (+10%) IN OPERATING LOSS
    * BELIEVES EUR 10 MILLION STATE-GUARANTEED LOAN, IN
COMBINATION
WITH ITS CURRENT CASH AND CASH EQUIVALENTS, WILL EXTEND ITS CASH
HORIZON INTO Q3 2021
    * TRYBECA-1 PHASE 3 TRIAL IN SECOND-LINE METASTATIC
PANCREATIC
CANCER: MORE THAN 95% OF THE APPROXIMATELY 500 PATIENTS ENROLLED
    * NOPHO-SPONSORED PHASE 2 TRIAL IN ACUTE LYMPHOBLASTIC
LEUKEMIA:
PATIENT ENROLLMENT COMPLETED: 55 PATIENTS ENROLLED

Source text for Eikon:  ID:nGNXw0jjq 
Further company coverage:  ERYP.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))